TMEM16A/ANO1 suppression improves response to antibody‐mediated targeted therapy of EGFR and HER2/ERBB2
Sign Up to like & getrecommendations! Published in 2017 at "Genes"
DOI: 10.1002/gcc.22450
Abstract: TMEM16A, a Ca2+‐activated Cl− channel, contributes to tumor growth in breast cancer and head and neck squamous cell carcinoma (HNSCC). Here, we investigated whether TMEM16A influences the response to EGFR/HER family‐targeting biological therapies. Inhibition of… read more here.
Keywords: egfr her2; improves response; tmem16a; antibody ... See more keywords